Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FSHR-directed CAR-T (IL-18 expressing)
- Development stage
- Unknown
- Lead developer
- The Second Xiangya Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
FSHR-directed CAR-T (IL-18 expressing) is an autologous chimeric antigen receptor (CAR) T-cell therapy engineered to target the follicle-stimulating hormone receptor (FSHR) and co-express interleukin-18 (IL-18). FSHR is highly expressed in several gynecological malignancies, particularly ovarian cancer, while having limited expression in non-reproductive tissues, making it a viable target for CAR-T therapy. The inclusion of IL-18, a proinflammatory cytokine, is intended to enhance the expansion, persistence, and antitumor activity of the CAR-T cells within the immunosuppressive tumor microenvironment. This "armored" CAR-T approach aims to overcome the challenges of treating solid tumors by modulating the local immune response. It is being developed by The Second Xiangya Hospital of Central South University for the treatment of FSHR-positive ovarian cancer.
- Other names
- CART-IL18CART-IL-18CART-IL 18FSHR-IL18-CARTFSHR-IL-18-CARTFSHR-IL 18-CART
02
Targets
FSHR (Follicle-stimulating hormone receptor)IL-18R (Interleukin-18 receptor complex)
Beyond the preview
Go deeper on FSHR-directed CAR-T (IL-18 expressing).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FSHR-directed CAR-T (IL-18 expressing).